Consequently, its logical therapeutical applications seems to be limited to restore physiological circulating levels in order to recover the clinical consequences of IGF-I deficiency, conditions where, despite continuous discrepancies, IGF-I treatment has never been related to oncogenesis. The gene discussed is IGF1; the disease is hyperinsulinemic hypoglycemia, familial, 4.